Research programme: defensin mimetic therapeutics - Innovation Pharmaceuticals

Drug Profile

Research programme: defensin mimetic therapeutics - Innovation Pharmaceuticals

Alternative Names: Arylamide series - PolyMedix; Bactericidal amphiphilic antibiotic compounds - PolyMedix; Calixarene series - PolyMedix; CTIX 1278; CTIX 1502; CTX 1807; Defensin-mimetics - PolyMedix; HDP mimetic compounds - Innovation Pharmaceuticals; Human defense protein mimetics - Innovation Pharmaceuticals; Hydrazide series - PolyMedix; PMX 1408; PMX 1502; PMX 196; PMX 225; PMX 231; PMX 243; PMX-10004; PMX-10033; PMX-10036; PMX-10052; PMX-10056; PMX-10065; PMX-10066; PMX-10067; PMX-10068; PMX-10070; PMX-10072; PMX-10098; PMX-30006; PMX-30016; PMX-30024; PMX-40007; PMX-50003; PMX-519; PMX-60006; PMX-60007; PMX-60014; PMX-70004; PMX-70008; Salicylamide series - PolyMedix

Latest Information Update: 09 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PolyMedix
  • Developer Innovation Pharmaceuticals
  • Class Calixarenes; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Defensin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acne vulgaris; Gram-negative infections; Mycoses; Proctitis; Rosacea
  • Suspended Anthrax; Hidradenitis suppurativa; Malaria; Tuberculosis

Most Recent Events

  • 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
  • 21 Apr 2015 Suspended - Preclinical for Hidradenitis suppurativa in USA (Topical)
  • 21 Apr 2015 Cellceutix plans a phase I trial for Gram-negative infections and Mycoses in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top